As of 2025-10-28, the Intrinsic Value of Kiniksa Pharmaceuticals Ltd (KNSA) is 22.98 USD. This KNSA valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 40.60 USD, the upside of Kiniksa Pharmaceuticals Ltd is -43.40%.
The range of the Intrinsic Value is 17.70 - 28.65 USD
Based on its market price of 40.60 USD and our intrinsic valuation, Kiniksa Pharmaceuticals Ltd (KNSA) is overvalued by 43.40%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (37.74) - (10.02) | (16.09) | -139.6% |
| DCF (Growth 10y) | (8.83) - (30.05) | (13.51) | -133.3% |
| DCF (EBITDA 5y) | 17.70 - 28.65 | 22.98 | -43.4% |
| DCF (EBITDA 10y) | 36.27 - 64.73 | 49.51 | 22.0% |
| Fair Value | 0.32 - 0.32 | 0.32 | -99.20% |
| P/E | 1.49 - 9.37 | 1.56 | -96.2% |
| EV/EBITDA | 18.02 - 25.55 | 21.79 | -46.3% |
| EPV | 8.30 - 9.88 | 9.09 | -77.6% |
| DDM - Stable | 0.46 - 1.37 | 0.91 | -97.8% |
| DDM - Multi | (1.94) - (4.63) | (2.75) | -106.8% |
| Market Cap (mil) | 3,008.87 |
| Beta | 0.50 |
| Outstanding shares (mil) | 74.11 |
| Enterprise Value (mil) | 2,816.83 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.07% |
| Cost of Debt | 5.00% |
| WACC | 7.37% |